Synthesis facilitates an understanding of the structural basis for translation inhibition by the lissoclimides

Nat Chem. 2017 Nov;9(11):1140-1149. doi: 10.1038/nchem.2800. Epub 2017 Jul 3.

Abstract

The lissoclimides are unusual succinimide-containing labdane diterpenoids that were reported to be potent cytotoxins. Our short semisynthesis and analogue-oriented synthesis approaches provide a series of lissoclimide natural products and analogues that expand the structure-activity relationships (SARs) in this family. The semisynthesis approach yielded significant quantities of chlorolissoclimide (CL) to permit an evaluation against the National Cancer Institute's 60-cell line panel and allowed us to obtain an X-ray co-crystal structure of the synthetic secondary metabolite with the eukaryotic 80S ribosome. Although it shares a binding site with other imide-based natural product translation inhibitors, CL engages in a particularly interesting and novel face-on halogen-π interaction between the ligand's alkyl chloride and a guanine residue. Our analogue-oriented synthesis provides many more lissoclimide compounds, which were tested against aggressive human cancer cell lines and for protein synthesis inhibitory activity. Finally, computational modelling was used to explain the SARs of certain key compounds and set the stage for the structure-guided design of better translation inhibitors.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / chemical synthesis
  • Antineoplastic Agents, Phytogenic / chemistry
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Biological Products / chemical synthesis
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Crystallography, X-Ray
  • Diterpenes / chemical synthesis*
  • Diterpenes / chemistry
  • Diterpenes / pharmacology*
  • Drug Screening Assays, Antitumor
  • Eukaryotic Initiation Factors / antagonists & inhibitors
  • Eukaryotic Initiation Factors / metabolism
  • Humans
  • Mice
  • Models, Molecular
  • Molecular Conformation
  • Peptides, Cyclic
  • Protein Biosynthesis / drug effects*
  • Succinimides / chemical synthesis*
  • Succinimides / chemistry
  • Succinimides / pharmacology*

Substances

  • Antineoplastic Agents, Phytogenic
  • Biological Products
  • Diterpenes
  • Eukaryotic Initiation Factors
  • Peptides, Cyclic
  • Succinimides
  • lissoclinamide 7
  • lissoclinamide 8
  • chlorolissoclimide

Associated data

  • PubChem-Substance/337015725
  • PubChem-Substance/337015732
  • PubChem-Substance/337015742
  • PubChem-Substance/337015753
  • PubChem-Substance/337015760
  • PubChem-Substance/337015761
  • PubChem-Substance/337015762
  • PubChem-Substance/337015763
  • PubChem-Substance/337015764
  • PubChem-Substance/337015726
  • PubChem-Substance/337015727
  • PubChem-Substance/337015728
  • PubChem-Substance/337015729
  • PubChem-Substance/337015730
  • PubChem-Substance/337015731
  • PubChem-Substance/337015733
  • PubChem-Substance/337015734
  • PubChem-Substance/337015735
  • PubChem-Substance/337015736
  • PubChem-Substance/337015737
  • PubChem-Substance/337015738
  • PubChem-Substance/337015739
  • PubChem-Substance/337015740
  • PubChem-Substance/337015741
  • PubChem-Substance/337015743
  • PubChem-Substance/337015744
  • PubChem-Substance/337015745
  • PubChem-Substance/337015746
  • PubChem-Substance/337015747
  • PubChem-Substance/337015748
  • PubChem-Substance/337015749
  • PubChem-Substance/337015750
  • PubChem-Substance/337015751
  • PubChem-Substance/337015752
  • PubChem-Substance/337015754
  • PubChem-Substance/337015755
  • PubChem-Substance/337015756
  • PubChem-Substance/337015757
  • PubChem-Substance/337015758
  • PubChem-Substance/337015759
  • PubChem-Substance/337015765
  • PubChem-Substance/337015785
  • PubChem-Substance/337015786
  • PubChem-Substance/337015787
  • PubChem-Substance/337015788
  • PubChem-Substance/337015789
  • PubChem-Substance/337015790
  • PubChem-Substance/337015791
  • PubChem-Substance/337015766
  • PubChem-Substance/337015767
  • PubChem-Substance/337015768
  • PubChem-Substance/337015769
  • PubChem-Substance/337015770
  • PubChem-Substance/337015771
  • PubChem-Substance/337015772
  • PubChem-Substance/337015773
  • PubChem-Substance/337015774
  • PubChem-Substance/337015775
  • PubChem-Substance/337015776
  • PubChem-Substance/337015777
  • PubChem-Substance/337015778
  • PubChem-Substance/337015779
  • PubChem-Substance/337015780
  • PubChem-Substance/337015781
  • PubChem-Substance/337015782
  • PubChem-Substance/337015783
  • PubChem-Substance/337015784